Tamir Diamond MD MSTR is a transplant hepatologist at Children's Hospital of Philadelphia and an assistant professor of pediatrics at Perelman School of Medicine, University of Pennsylvania. His research interest focuses on immune mechanisms of Pediatric and Neonatal Acute Liver Failure. He is a member of the inaugural Clinical In Vivo Gene Therapy team at Children's Hospital of Philadelphia, the first interdisciplinary team in the US focusing on treating complications arising for children receiving novel Gene therapies.

Dr. Elizabeth Phillips is a physician scientist clinically trained in Infectious diseases, immunology and clinical pharmacology who has established new clinical and research programs in drug hypersensitivity, pharmacogenomics and personalized immunology across different healthcare systems. She has published over 450 peer reviewed articles and book chapters related to hypersensitivity reactions to drugs and vaccines.

Dr. Jonathan Sexton is faculty in the Department of Internal Medicine in the Division of Gastroenterology and Hepatology, and the College of Pharmacy, Medicinal Chemistry at the University of Michigan. Dr. Sexton is a translational scientist with expertise in artificial intelligence-enhanced drug discovery and development. His research focuses on advancing lead compounds toward clinical applications in various therapeutic areas, particularly in liver and gastrointestinal diseases.

.

I am a transplant hepatologist with a research focus at the intersection of nephrology and hepatology.

Dr. Juan G. Abraldes is a Transplant Hepatologist, Professor and Director of the Liver Unit at the University of Alberta. <br><br>He did his MD at the University of Santiago de Compostela, Spain, and got his GI and hepatology training in Barcelona. He did a postdoctoral training at Yale University (2003–2004). <br><br>His main interest is the diagnosis, risk prediction and management of chronic liver disease. He has co-chaired the AASLD guidelines for TIPS and RT0 (2024), and co-authored the AASLD portal hypertension guidelines (2016).

Dr. Constantine (Dean) Karvellas is a Professor of Critical Care Medicine at the University of Alberta and an Adjunct Professor in the School of Public Health Sciences. He has been an attending intensivist in the E. Garner King General Systems Intensive Care Unit since 2009 and is involved with the Liver Transplant program as a Hepatologist. Dr. Karvellas is the only Canadian co-investigator in the NIH-funded United States Acute Liver Failure study group (US ALFSG).

I am an American, Spanish-trained physician, quadruple board-certified in Internal Medicine, Gastroenterology, Transplant Hepatology and Obesity Medicine. Since I joined the VA in August 2016, I have been pursuing the triple threat: to boost hepatology education of residents and fellows, to have clinical excellence, and to excel in hepatology research. My areas of interests are outcomes research in chronic liver diseases, acute-on-chronic liver diseases and prognostic modeling.

Dr. Jacqueline O'Leary began her pursuit of research as an undergraduate at Stanford investigating drug development, continued at UCSF where she received and MD with thesis for work in cellular and molecular biology. Following her internal medicine residency at UT Southwestern in Dallas, Dr. O'Leary did a GI fellowship and transplant Hepatology fellowship at Massachusetts General Hospital. Her post-doctoral research there at Harvard focused on immunology. Afterward, she completed a Master's in Public Health from the Harvard School of Public Health.

I am an Associate Professor of Medicine in the Karsh Division of Gastroenterology and Hepatology and the Medical Director of the Liver Cancer Program at Cedars-Sinai Cancer. My research program has been focused on clinical and translational research of liver cancer. I have extensive experience in epidemiology of liver cirrhosis risk stratification, surveillance, cancer early detection, diagnosis, and treatment.